Tulmimetostat DL1 QD + Tulmimetostat DL2 QD + Tulmimetostat DL3 QD + Tulmimetostat Doses 1 or 2 QD + Tulmimetostat RP2D QD + JSB462 Dose 1 QD + JSB462 Dose 2 QD + JSB462 QD + Standard of Care (SoC)

Phase 1/2Recruiting

1 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Progressive Metastatic Castrate Resistant Prostate Cancer

Conditions

Progressive Metastatic Castrate Resistant Prostate Cancer

Trial Timeline

Oct 15, 2025 → Dec 17, 2030

NCT ID

NCT07206056

About Tulmimetostat DL1 QD + Tulmimetostat DL2 QD + Tulmimetostat DL3 QD + Tulmimetostat Doses 1 or 2 QD + Tulmimetostat RP2D QD + JSB462 Dose 1 QD + JSB462 Dose 2 QD + JSB462 QD + Standard of Care (SoC)

Tulmimetostat DL1 QD + Tulmimetostat DL2 QD + Tulmimetostat DL3 QD + Tulmimetostat Doses 1 or 2 QD + Tulmimetostat RP2D QD + JSB462 Dose 1 QD + JSB462 Dose 2 QD + JSB462 QD + Standard of Care (SoC) is a phase 1/2 stage product being developed by Novartis for Progressive Metastatic Castrate Resistant Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07206056. Target conditions include Progressive Metastatic Castrate Resistant Prostate Cancer.

What happened to similar drugs?

2 of 20 similar drugs in Progressive Metastatic Castrate Resistant Prostate Cancer were approved

Approved (2) Terminated (4) Active (14)

🔄Enzalutamide + PlaceboAstellas PharmaPhase 3

🔄HRS-4357 injection + Enzalutamide；AbirateroneJiangsu Hengrui MedicinePhase 3

🔄Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3

❌FTY720 + PlaceboNovartisPhase 3

✅BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved

🔄BAF312 + PlaceboNovartisPhase 3

✅Imatinib mesylateNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07206056	Phase 1/2	Recruiting	Oct 15, 2025	Dec 17, 2030	Progressive Metastatic Castrate Resistant Prostate Cancer

Competing Products

20 competing products in Progressive Metastatic Castrate Resistant Prostate Cancer

See all competitors

Product	Company	Stage	Hype Score
AP01	Avalyn Pharmaceuticals	Phase 2	32
Enzalutamide + Placebo	Astellas Pharma	Phase 3	40
Enzalutamide	Astellas Pharma	Phase 2	35
dirucotide + Placebo	Eli Lilly	Phase 2/3	38
dirucotide	Eli Lilly	Phase 2/3	30
HRS-4357 injection + Enzalutamide；Abiraterone	Jiangsu Hengrui Medicine	Phase 3	47
ABBV-8E12 + Placebo solution for IV infusion on Day 15	AbbVie	Phase 2	27
Placebo + ABBV-8E12	AbbVie	Phase 2	27
ABBV-8E12	AbbVie	Phase 1	29
AZD4635 + Durvalumab + Cabazitaxel	AstraZeneca	Phase 2	35
antisense oligonucleotide + placebo	Novartis	Phase 1	29
Trametinib 2 mg	Novartis	Pre-clinical	26
Everolimus	Novartis	Phase 2	35
sunitinib + everolimus + chemotherapies recommended in france	Novartis	Pre-clinical	26
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)	Novartis	Phase 3	47
FTY720 + Placebo	Novartis	Phase 3	32
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273	Novartis	Approved	43
Mayzent	Novartis	Pre-clinical	26
BAF312 + Placebo	Novartis	Phase 3	40
Imatinib mesylate	Novartis	Approved	43